MHE January 2020

Novel drugs, value-based contracting, biosimilars, and regulatory activity addressing costs will be among the hot button issues in the coming year.

Health executives weigh in on what success will mean to them in 2020.

Risk-stratification and electronic triage programs are improving patient care and decreasing costs for health systems.

Increasing chronic care needs are incentivizing direct-tech services.

Payer education, evidence critical to providing cost-effective, beneficial treatment in pharmacogenetics.

Many of the challenges that face our industry in 2020 will require a fresh way of thinking.

Here are healthcare leaders’ top challenges, as well as coping strategies

The new and proposed federal regulations, as well as state laws, that are trending across the United States.

Here are four programs making a difference.

Here are the top drugs expected to be approved this year and their financial impact.

Strategies to get the most value out of current and future oncology payment models

Leadership skills honed in midst of disaster.